SCHEMBL23810206

SCHEMBL23810206

C=CC(=O)NCCCCNC(=O)c1ccc(CN=[N+]=[N-])nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ APOBEC3A P31941 1/20 0.38
▸ APOBEC3G Q9HC16 1/20 0.38
▸ ALOX15 P16050 2/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ KEAP1 Q14145 1/20 0.35
▸ NFE2L2 Q16236 1/20 0.35
▸ ZDHHC20 Q5W0Z9 1/20 0.35
▸ ZDHHC2 Q9UIJ5 1/20 0.35
▸ TGM2 P21980 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23810201 0.85 KDM4E (0.45) KDM4EKDM4CNPC1RAB9AAPOBEC3A
SCHEMBL15285087 0.84 MAPK1 (0.53) KDM4EKDM4CHDAC3HDAC1HDAC2
SCHEMBL23801525 0.83 GRM5 (0.37) KDM4EKDM4CNPC1RAB9AAPOBEC3A
SCHEMBL22150633 0.81 KDM4E (0.45) KDM4EKDM4CNPC1RAB9AAPOBEC3A
SCHEMBL15285036 0.81 MAOB (0.44) KDM4EKDM4CNPC1RAB9AHDAC3
SCHEMBL22150196 0.81 HDAC8 (0.39) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL16560328 0.80 KDM4E (0.41) KDM4EKDM4CNPC1RAB9AAPOBEC3A
SCHEMBL22149736 0.80 HDAC8 (0.40) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL22149955 0.80 SMN1; SMN2 (0.38) KDM4EHDAC3HDAC1HDAC2HDAC8
SCHEMBL22149715 0.80 KDM4E (0.40) KDM4EKDM4CNPC1RAB9AAPOBEC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018103-B2 Flow cell and methods ILLUMINA CAMBRIDGE LIMITED (GB) 2024-06-25 — — US disclosed
US-20220372182-A1 FLOW CELL AND METHODS ILLUMINA CAMBRIDGE LIMITED (GB) 2022-11-24 — — US disclosed
US-20220185927-A1 HYDROGEL ILLUMINA CAMBRIDGE LIMITED (GB) 2022-06-16 — — US disclosed
US-20210284609-A1 HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS ILLUMINA CAMBRIDGE LIMITED (GB) 2021-09-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284609-A1 HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS POLL, PCNA, DNMT3A KDM4E 3663/4885KDM4C 1062/4885NPC1 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback